Cargando…

Modelling HIV-1 2-LTR dynamics following raltegravir intensification

A model of reservoir activation and viral replication is introduced accounting for the production of 2-LTR HIV-1 DNA circles following antiviral intensification with the HIV integrase inhibitor raltegravir, considering contributions of de novo infection events and exogenous sources of infected cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Rutao, Cardozo, E. Fabian, Piovoso, Michael J., Wu, Hulin, Buzon, Maria J., Martinez-Picado, Javier, Zurakowski, Ryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2013
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673152/ https://www.ncbi.nlm.nih.gov/pubmed/23658114 http://dx.doi.org/10.1098/rsif.2013.0186

Ejemplares similares

HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
por: Luo, Rutao, et al.
Publicado: (2012)

Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy
por: Luo, Rutao, et al.
Publicado: (2011)

HIV 2-LTR experiment design optimization
por: Cannon, LaMont, et al.
Publicado: (2018)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence
por: Martinez-Picado, Javier, et al.
Publicado: (2018)

An Integrated Spatial Dynamics—Pharmacokinetic Model Explaining Poor Penetration of Anti-retroviral Drugs in Lymph Nodes
por: Jagarapu, Aditya, et al.
Publicado: (2020)

Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
por: Puthanakit, Thanyawee, et al.
Publicado: (2018)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2011)

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals
por: Massanella, Marta, et al.
Publicado: (2014)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Long-term efficacy and safety of raltegravir in the management of HIV infection
por: Liedtke, Michelle D, et al.
Publicado: (2014)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gp(high) cells and correlates with HIV-1 viral load
por: Minuesa, Gerard, et al.
Publicado: (2016)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

Low raltegravir transfer into the breastmilk of a woman living with HIV
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2020)

HIV UTR, LTR, and Epigenetic Immunity
por: Zhang, Jielin, et al.
Publicado: (2022)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance
por: Fun, Axel, et al.
Publicado: (2018)

Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy
por: White, Jennifer A., et al.
Publicado: (2022)

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
por: Charpentier, Charlotte, et al.
Publicado: (2010)

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013)

555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
por: Lackey, Philip, et al.
Publicado: (2018)

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
por: Hosoda, Tomohiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6chhhae9lm76drrecnj381hjo3